Vera Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Vera Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 2 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Vera Therapeutics: 4 sponsored US clinical trials, 2 recruiting.

Vera Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Berger Disease, with 2 trials.

Upper-quartile sponsor footprint

Vera Therapeutics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Vera Therapeutics pipeline

2 recruiting of 4 indexed (50% open); 1 completed (25%).

Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Berger Disease (2 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vera Therapeutics: open-pipeline peers nationwide

Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Vera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60%80% Total trials Recruiting share Vera Therapeutics4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab1200 Pharma1ST Biotherapeutics3ive Labs7 Hills Pharma
Vera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vera Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Vera Therapeutics page

4 registered trials is a research-attention snapshot, not an endorsement of Vera Therapeutics or any single study.

  • 2 of Vera Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Berger Disease is the condition Vera Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Berger Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vera Therapeutics pipeline card: 4 registered trials from official public datasets.Report a data error.